Autopsy report · NCT04880343

Clinical Study to Evaluate the Efficacy of the Dietary Supplement UROMANNOSA® in Women With Recurrent Lower Urinary Tract Infections

“Difficulties in recruiting the control arm in accordance with the protocol prevent the study population from being reached.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Suspended: paused, and may or may not restart.
• 108 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Na

Sponsor

Carmen Gonzalez Enguita

Sponsor type

University, hospital or other

Conditions

Lower Urinary Tract Infection

Interventions

Group (A); Group (B)

Participants

108 (planned, not actual)

Sites

1

Countries

Spain

Trials that died the same way

• Impact of CTO PCI (Chronic Total Occlusion Percutaneous Intervention) on Regular Physical Activity
  “Recruitment not possible in study location given study population.” (59% match in meaning)
• Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease
  “difficulties recruiting this population for study population” (59% match in meaning)
• Diagnostic Performance of an Antigen Test for SARS-CoV-2 Infection (COVID-19)
  “Difficulty with recruiting for the study and with staffing the study.” (59% match in meaning)
• DLBS1033 for the Treatment of Acute Ischemic Stroke
  “Major technical hindrance in recruitment.” (58% match in meaning)
• Efficacy of EndoClot™ Spraying After Endoscopic Resection of Large Colorectal Polyps
  “insufficient recruitment of study patients” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.